News
PHAR
13.16
+7.08%
0.87
Weekly Report: what happened at PHAR last week (1102-1106)?
Weekly Report · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Intensity Therapeutics, Inc. (INTS), Pharming Group (PHAR)
TipRanks · 3d ago
MHRA Approves Pharming Group N.V.’s Joenja as First Treatment Specifically for Children with APDS in the U.K.
NASDAQ · 3d ago
Pharming’s Joenja Approved for Children With APDS in U.K.
TipRanks · 3d ago
Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets
Benzinga · 4d ago
Weekly Report: what happened at PHAR last week (1026-1030)?
Weekly Report · 11/02 10:16
Pharming Group Price Target Raised to $41.00/Share From $38.00 by Canaccord Genuity
Dow Jones · 10/29 22:15
Pharming Group Is Maintained at Buy by Canaccord Genuity
Dow Jones · 10/29 22:15
Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41
Benzinga · 10/29 22:05
Pharming price target raised to $41 from $38 at Canaccord
TipRanks · 10/29 11:45
Pantginis Maintains Buy on Strong Ruconest and Joenja Momentum; $37 Price Target Reaffirmed
TipRanks · 10/27 16:35
Pharming Q3 2026 Earnings Call Transcript
Benzinga · 10/27 13:40
Pharming reports Q3 EPS 3c, consensus 7c
TipRanks · 10/27 09:35
Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est
Benzinga · 10/27 08:06
Pharming Q3 Revenue Jumps 21%, CVID Data Due In November
NASDAQ · 10/27 07:48
Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate
Benzinga · 10/27 06:13
Weekly Report: what happened at PHAR last week (1019-1023)?
Weekly Report · 10/26 10:16
Selective Insurance, Crown Castle, UWM Holdings And Other Big Stocks Moving Higher On Friday
Benzinga · 10/23 14:40
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Pharming Group (PHAR) and BioNTech SE (BNTX)
TipRanks · 10/23 12:10
Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings
Benzinga · 10/22 16:31
More
Webull provides a variety of real-time PHAR stock news. You can receive the latest news about Pharming Group N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.